Trial Profile
Phase IB/Randomized Phase II Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ganitumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Aug 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 22 Nov 2011 New trial record